Niels P Riksen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2011097/publications.pdf

Version: 2024-02-01

		57752	43886
159	10,031	44	91
papers	citations	h-index	g-index
168	168	168	12350
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Clonal Hematopoiesis Is Associated With Low CD4 Nadir and Increased Residual HIV Transcriptional Activity in Virally Suppressed Individuals With HIV. Journal of Infectious Diseases, 2022, 225, 1339-1347.	4.0	17
2	An integrative genomics approach identifies KDM4 as a modulator of trained immunity. European Journal of Immunology, 2022, 52, 431-446.	2.9	22
3	Immune modulatory effects of progesterone on oxLDL-induced trained immunity in monocytes. Journal of Leukocyte Biology, 2022, 112, 279-288.	3.3	14
4	Discovery, diversity, and functional associations of crAss-like phages in human gut metagenomes from four Dutch cohorts. Cell Reports, 2022, 38, 110204.	6.4	30
5	Relation Between Plasma Proteomics Analysis and Major Adverse Cardiovascular Events in Patients With Stable Coronary Artery Disease. Frontiers in Cardiovascular Medicine, 2022, 9, 731325.	2.4	7
6	The role of the mineralocorticoid receptor in immune cells in cardiovascular disease. British Journal of Pharmacology, 2022, 179, 3135-3151.	5.4	16
7	Innate immune cells in the pathophysiology of calcific aortic valve disease: lessons to be learned from atherosclerotic cardiovascular disease?. Basic Research in Cardiology, 2022, 117, 28.	5.9	9
8	The Hyperintense study: Assessing the effects of induced blood pressure increase and decrease on MRI markers of cerebral small vessel disease: Study rationale and protocol. European Stroke Journal, 2022, 7, 331-338.	5.5	2
9	Trained Immunity. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 55-61.	2.4	21
10	Trained Immunity in Atherosclerotic Cardiovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 62-69.	2.4	39
11	Immunometabolic control of trained immunity. Molecular Aspects of Medicine, 2021, 77, 100897.	6.4	71
12	Trained immunity, tolerance, priming and differentiation: distinct immunological processes. Nature Immunology, 2021, 22, 2-6.	14.5	274
13	Reduced concentrations of the B cell cytokine interleukin 38 are associated with cardiovascular disease risk in overweight subjects. European Journal of Immunology, 2021, 51, 662-671.	2.9	23
14	An integrative model of cardiometabolic traits identifies two types of metabolic syndrome. ELife, 2021, 10, .	6.0	4
15	Prosaposin mediates inflammation in atherosclerosis. Science Translational Medicine, 2021, 13, .	12.4	42
16	InÂvitro induction of trained immunity in adherent human monocytes. STAR Protocols, 2021, 2, 100365.	1.2	42
17	Growth differentiation factor 15 levels are similar in primary aldosteronism and essential hypertension and do not predict arterial inflammation. Journal of Hypertension, 2021, 39, 593-596.	0.5	0
18	Trained Immunity: Reprogramming Innate Immunity in Health and Disease. Annual Review of Immunology, 2021, 39, 667-693.	21.8	146

#	Article	IF	CITATIONS
19	Neuroinflammation in cognitive decline post-cardiac surgery (the FOCUS study): an observational study protocol. BMJ Open, 2021, 11, e044062.	1.9	2
20	Oral Microbiome in Relation to Periodontitis Severity and Systemic Inflammation. International Journal of Molecular Sciences, 2021, 22, 5876.	4.1	38
21	Pro-inflammatory Monocyte Phenotype During Acute Progression of Cerebral Small Vessel Disease. Frontiers in Cardiovascular Medicine, 2021, 8, 639361.	2.4	8
22	An Explorative Study on Monocyte Reprogramming in the Context of Periodontitis In Vitro and In Vivo. Frontiers in Immunology, 2021, 12, 695227.	4.8	13
23	Understanding the increased risk of infections in diabetes: innate and adaptive immune responses in type 1 diabetes. Metabolism: Clinical and Experimental, 2021, 121, 154795.	3.4	11
24	Hyperglycemia Induces Trained Immunity in Macrophages and Their Precursors and Promotes Atherosclerosis. Circulation, 2021, 144, 961-982.	1.6	109
25	Hyperglycemic Memory of Innate Immune Cells Promotes In Vitro Proinflammatory Responses of Human Monocytes and Murine Macrophages. Journal of Immunology, 2021, 206, 807-813.	0.8	33
26	oxLDL-Induced Trained Immunity Is Dependent on Mitochondrial Metabolic Reprogramming. Immunometabolism, 2021, 3, e210025.	6.0	7
27	Characterization of gut microbial structural variations as determinants of human bile acid metabolism. Cell Host and Microbe, 2021, 29, 1802-1814.e5.	11.0	43
28	Aldosterone induces trained immunity: the role of fatty acid synthesis. Cardiovascular Research, 2020, 116, 317-328.	3.8	49
29	Pathophysiology and diagnosis of coronary microvascular dysfunction in ST-elevation myocardial infarction. Cardiovascular Research, 2020, 116, 787-805.	3.8	119
30	Arterial Wall Inflammation and Increased Hematopoietic Activity in Patients With Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1967-e1980.	3.6	27
31	Genetic and Microbial Associations to Plasma and Fecal Bile Acids in Obesity Relate to Plasma Lipids and Liver Fat Content. Cell Reports, 2020, 33, 108212.	6.4	55
32	A High Glycemic Burden Relates to Functional and Metabolic Alterations of Human Monocytes in Patients With Type 1 Diabetes. Diabetes, 2020, 69, 2735-2746.	0.6	9
33	Hydroxychloroquine Inhibits the Trained Innate Immune Response to Interferons. Cell Reports Medicine, 2020, 1, 100146.	6.5	24
34	Macrophage mitochondrial superoxides as a target for atherosclerotic disease treatment. International Journal of Biochemistry and Cell Biology, 2020, 129, 105883.	2.8	1
35	Gut microbial co-abundance networks show specificity in inflammatory bowel disease and obesity. Nature Communications, 2020, 11, 4018.	12.8	80
36	Acromegaly, inflammation and cardiovascular disease: a review. Reviews in Endocrine and Metabolic Disorders, 2020, 21, 547-568.	5.7	29

#	Article	IF	Citations
37	Sex-Specific Regulation of Inflammation and Metabolic Syndrome in Obesity. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 1787-1800.	2.4	77
38	Vasculometabolic and Inflammatory Effects of Aldosterone in Obesity. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2719-2731.	3.6	8
39	Platelet Inhibition, Endothelial Function, and Clinical Outcome in Patients Presenting With STâ€Segment–Elevation Myocardial Infarction Randomized to Ticagrelor Versus Prasugrel Maintenance Therapy: Longâ€Term Followâ€Up of the REDUCEâ€MVI Trial. Journal of the American Heart Association, 2020, 9. e014411.	3.7	15
40	Defining trained immunity and its role in health and disease. Nature Reviews Immunology, 2020, 20, 375-388.	22.7	1,345
41	Trained Immunity: Linking Obesity and Cardiovascular Disease across the Life-Course?. Trends in Endocrinology and Metabolism, 2020, 31, 378-389.	7.1	40
42	Rewiring of glucose metabolism defines trained immunity induced by oxidized low-density lipoprotein. Journal of Molecular Medicine, 2020, 98, 819-831.	3.9	59
43	The Set7 Lysine Methyltransferase Regulates Plasticity in Oxidative Phosphorylation Necessary for Trained Immunity Induced by \hat{I}^2 -Glucan. Cell Reports, 2020, 31, 107548.	6.4	76
44	Catecholamines Induce Trained Immunity in Monocytes In Vitro and In Vivo. Circulation Research, 2020, 127, 269-283.	4.5	76
45	New live attenuated tuberculosis vaccine MTBVAC induces trained immunity and confers protection against experimental lethal pneumonia. PLoS Pathogens, 2020, 16, e1008404.	4.7	58
46	Reprogramming of bone marrow myeloid progenitor cells in patients with severe coronary artery disease. ELife, 2020, 9, .	6.0	23
47	Abstract 15495: Interleukin 18 Binding Protein Predicts Future Cardiovascular Morbidity and Mortality in Subjects Undergoing Coronary Angiography - the Casablanca Cohort. Circulation, 2020, 142, .	1.6	0
48	Sixteenâ€Week Physical Activity Intervention in Subjects With Increased Cardiometabolic Risk Shifts Innate Immune Function Towards a Less Proinflammatory State. Journal of the American Heart Association, 2019, 8, e013764.	3.7	26
49	Plasma levels of the cardiovascular protective endogenous nucleoside adenosine are reduced in patients with primary aldosteronism without affecting ischaemiaâ€reperfusion injury: A prospective caseâ€control study. European Journal of Clinical Investigation, 2019, 49, e13180.	3.4	4
50	Trained immunity and diabetic vascular disease. Clinical Science, 2019, 133, 195-203.	4.3	22
51	Treatment with Statins Does Not Revert Trained Immunity in Patients with Familial Hypercholesterolemia. Cell Metabolism, 2019, 30, 1-2.	16.2	130
52	Oligomeric S100A4 Is Associated With Monocyte Innate Immune Memory and Bypass of Tolerance to Subsequent Stimulation With Lipopolysaccharides. Frontiers in Immunology, 2019, 10, 791.	4.8	33
53	Immunometabolism orchestrates training of innate immunity in atherosclerosis. Cardiovascular Research, 2019, 115, 1416-1424.	3.8	44
54	Increased proteinase 3 and neutrophil elastase plasma concentrations are associated with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes. Molecular Medicine, 2019, 25, 16.	4.4	44

#	Article	IF	CITATIONS
55	Gut Microbial Associations to Plasma Metabolites Linked to Cardiovascular Phenotypes and Risk. Circulation Research, 2019, 124, 1808-1820.	4.5	137
56	Effect of two dosages of sodium chloride intake on the blood pressure response to caffeinated coffee in humans <i>in vivo</i> . International Journal of Food Sciences and Nutrition, 2019, 70, 1014-1019.	2.8	2
57	OP0221â€OLIGOMERIC S100A4 INDUCES MONOCYTE INNATE IMMUNE MEMORY. , 2019, , .		O
58	Trained immunity and atherosclerotic cardiovascular disease. Current Opinion in Lipidology, 2019, 30, 395-400.	2.7	18
59	Multidisciplinary care for people with Parkinson's disease: the new kids on the block!. Expert Review of Neurotherapeutics, 2019, 19, 145-157.	2.8	45
60	Increased NEFA levels reduce blood Mg2+ in hypertriacylglycerolaemic states via direct binding of NEFA to Mg2+. Diabetologia, 2019, 62, 311-321.	6.3	14
61	Evaluation of Microvascular Injury in Revascularized Patients With ST-Segment–Elevation Myocardial Infarction Treated With Ticagrelor Versus Prasugrel. Circulation, 2019, 139, 636-646.	1.6	40
62	The mineralocorticoid receptor as a modulator of innate immunity and atherosclerosis. Cardiovascular Research, 2018, 114, 944-953.	3.8	48
63	Trained Innate Immunity as a Novel Mechanism Linking Infection and the Development of Atherosclerosis. Circulation Research, 2018, 122, 664-669.	4.5	107
64	Metabolic Induction of Trained Immunity through the Mevalonate Pathway. Cell, 2018, 172, 135-146.e9.	28.9	485
65	Western Diet Triggers NLRP3-Dependent Innate Immune Reprogramming. Cell, 2018, 172, 162-175.e14.	28.9	705
66	Interleukin-32 upregulates the expression of ABCA1 and ABCG1 resulting in reduced intracellular lipid concentrations in primary human hepatocytes. Atherosclerosis, 2018, 271, 193-202.	0.8	18
67	Monocyte and haematopoietic progenitor reprogramming as common mechanism underlying chronic inflammatory and cardiovascular diseases. European Heart Journal, 2018, 39, 3521-3527.	2.2	44
68	Monocyte and macrophage immunometabolism in atherosclerosis. Seminars in Immunopathology, 2018, 40, 203-214.	6.1	150
69	The acute effect of black tea consumption on resistance artery endothelial function in healthy subjects. A randomized controlled trial. Clinical Nutrition ESPEN, 2018, 23, 41-47.	1.2	5
70	Epigenetics in diabetic nephropathy, immunity and metabolism. Diabetologia, 2018, 61, 6-20.	6.3	65
71	Getting to the marrow of trained immunity. Epigenomics, 2018, 10, 1151-1154.	2.1	3
72	Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association–European Society of Cardiology. European Heart Journal, 2018, 39, 4243-4254.	2.2	171

#	Article	IF	CITATIONS
73	Metabolism of innate immune cells. Current Opinion in Lipidology, 2018, 29, 359-367.	2.7	22
74	Trained Immunity Characteristics Are Associated With Progressive Cerebral Small Vessel Disease. Stroke, 2018, 49, 2910-2917.	2.0	44
75	Short-Term Hypoxia Dampens Inflammation in vivo via Enhanced Adenosine Release and Adenosine 2B Receptor Stimulation. EBioMedicine, 2018, 33, 144-156.	6.1	47
76	Investigating the origin and evolution of cerebral small vessel disease: The RUN DMC – InTENse study. European Stroke Journal, 2018, 3, 369-378.	5.5	14
77	Microbial Impact on Plasma Metabolites is Linked to the Cardiovascular Risk and Phenotypes. Atherosclerosis Supplements, 2018, 32, 118-119.	1.2	2
78	Epigenetics and Trained Immunity. Antioxidants and Redox Signaling, 2018, 29, 1023-1040.	5.4	176
79	Be aware, innate immune cells remember. Aging, 2018, 10, 2218-2219.	3.1	3
80	Planarians SET New Paths for Innate Immune Memory. EBioMedicine, 2017, 20, 7-8.	6.1	2
81	Plasma galectin-3 concentrations in patients with primary aldosteronism. Journal of Hypertension, 2017, 35, 1849-1856.	0.5	3
82	Impact of lifelong exercise training on endothelial ischemia-reperfusion and ischemic preconditioning in humans. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2017, 312, R828-R834.	1.8	18
83	Oxidized phospholipids on lipoprotein(a) induce epigenetic reprogramming and an increased pro-atherogenic response in human monocytes. Atherosclerosis, 2017, 263, e28.	0.8	0
84	Specific and Complex Reprogramming of Cellular Metabolism in Myeloid Cells during Innate Immune Responses. Cell Metabolism, 2017, 26, 142-156.	16.2	144
85	A randomised trial on the effect of anti-platelet therapy on the systemic inflammatory response in human endotoxaemia. Thrombosis and Haemostasis, 2017, 117, 1798-1807.	3.4	34
86	A systematic review and meta-analysis of the protective effects of metformin in experimental myocardial infarction. PLoS ONE, 2017, 12, e0183664.	2.5	30
87	Isolated arterial calcifications of the lower extremities: A clue for NT5E mutation. International Journal of Cardiology, 2016, 212, 248-250.	1.7	12
88	BCG lowers plasma cholesterol levels and delays atherosclerotic lesion progression in mice. Atherosclerosis, 2016, 251, 6-14.	0.8	27
89	Eplerenone does not limit ischemia–reperfusion injury in human myocardial tissue. International Journal of Cardiology, 2016, 216, 110-113.	1.7	5
90	The effect of dipyridamole on the pharmacokinetics of metformin: a randomized crossover study in healthy volunteers. European Journal of Clinical Pharmacology, 2016, 72, 725-730.	1.9	9

#	Article	IF	Citations
91	Long-term activation of the innate immune system in atherosclerosis. Seminars in Immunology, 2016, 28, 384-393.	5.6	75
92	Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans. Circulation, 2016, 134, 611-624.	1.6	396
93	Diabetes propels the risk for cardiovascular disease: sweet monocytes becoming aggressive?. Cellular and Molecular Life Sciences, 2016, 73, 4675-4684.	5.4	49
94	Glutaminolysis and Fumarate Accumulation Integrate Immunometabolic and Epigenetic Programs in Trained Immunity. Cell Metabolism, 2016, 24, 807-819.	16.2	584
95	<i>In Vitro</i> Experimental Model of Trained Innate Immunity in Human Primary Monocytes. Vaccine Journal, 2016, 23, 926-933.	3.1	239
96	Innate immune cell activation and epigenetic remodeling in symptomatic and asymptomatic atherosclerosis in humans inÂvivo. Atherosclerosis, 2016, 254, 228-236.	0.8	163
97	Heart failure is associated with exaggerated endothelial ischaemia–reperfusion injury and attenuated effect of ischaemic preconditioning. European Journal of Preventive Cardiology, 2016, 23, 33-40.	1.8	25
98	Differential effects of platelets and platelet inhibition by ticagrelor on TLR2- and TLR4-mediated inflammatory responses. Thrombosis and Haemostasis, 2015, 113, 1035-1045.	3.4	40
99	Effects of the 34C>T Variant of the AMPD1 Gene on Immune Function, Multi-Organ Dysfunction, and Mortality in Sepsis Patients. Shock, 2015, 44, 542-547.	2.1	2
100	Plasma cholesteryl ester transfer protein is predominantly derived from Kupffer cells. Hepatology, 2015, 62, 1710-1722.	7.3	60
101	Ticagrelor Does Not Inhibit Adenosine Transport at Relevant Concentrations: A Randomized Cross-Over Study in Healthy Subjects In Vivo. PLoS ONE, 2015, 10, e0137560.	2.5	23
102	The Epigenetic Memory of Monocytes and Macrophages as a Novel Drug Target in Atherosclerosis. Clinical Therapeutics, 2015, 37, 914-923.	2.5	52
103	Pharmacological treatment of aldosterone excess. , 2015, 154, 120-133.		31
104	Effect of metformin pretreatment on myocardial injury during coronary artery bypass surgery in patients without diabetes (MetCAB): a double-blind, randomised controlled trial. Lancet Diabetes and Endocrinology, the, 2015, 3, 615-623.	11.4	45
105	Preface. European Journal of Pharmacology, 2015, 763, 1-2.	3.5	2
106	Trained immunity: A smart way to enhance innate immune defence. Molecular Immunology, 2015, 68, 40-44.	2.2	147
107	Determinants of the Efficacy of Cardiac Ischemic Preconditioning: A Systematic Review and Meta-Analysis of Animal Studies. PLoS ONE, 2015, 10, e0142021.	2.5	36
108	Impact of Metformin on Endothelial Ischemia-Reperfusion Injury in Humans In Vivo: A Prospective Randomized Open, Blinded-Endpoint Study. PLoS ONE, 2014, 9, e96062.	2.5	13

#	Article	IF	CITATIONS
109	The Effect of Eplerenone on Adenosine Formation in Humans In Vivo: A Double-Blinded Randomised Controlled Study. PLoS ONE, 2014, 9, e111248.	2.5	5
110	Trained innate immunity as a mechanistic link between sepsis and atherosclerosis. Critical Care, 2014, 18, 645.	5.8	8
111	The cardiovascular effects of metformin. Current Opinion in Lipidology, 2014, 25, 446-451.	2.7	10
112	It takes more than one CAMERA to study cardiovascular protection by metformin. Lancet Diabetes and Endocrinology,the, 2014, 2, 105-106.	11.4	5
113	The cardioprotective effects of mineralocorticoid receptor antagonists. , 2014, 142, 72-87.		25
114	Oxidized Low-Density Lipoprotein Induces Long-Term Proinflammatory Cytokine Production and Foam Cell Formation via Epigenetic Reprogramming of Monocytes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 1731-1738.	2.4	486
115	The effect of remote ischemic preconditioning on exercise-induced plasma troponin I appearance in healthy volunteers. International Journal of Cardiology, 2013, 168, 1612-1613.	1.7	7
116	Metformin improves survival in intensive care unit patients, but why?. Critical Care, 2013, 17, 471.	5.8	1
117	Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner. Cardiovascular Diabetology, 2013, 12, 154.	6.8	81
118	Metformin Therapy in Diabetes: The Role of Cardioprotection. Current Atherosclerosis Reports, 2013, 15, 314.	4.8	56
119	Complete remission of coronary vasculitis in Churg–Strauss Syndrome by prednisone and cyclophosphamide. Clinical Rheumatology, 2013, 32, 41-42.	2.2	6
120	Trained innate immunity and atherosclerosis. Current Opinion in Lipidology, 2013, 24, 487-492.	2.7	51
121	Aging attenuates the protective effect of ischemic preconditioning against endothelial ischemia-reperfusion injury in humans. American Journal of Physiology - Heart and Circulatory Physiology, 2013, 304, H1727-H1732.	3.2	69
122	Limitation of myocardial ischemia-reperfusion injury in clinical practice. Current Opinion in Lipidology, 2012, 23, 588-590.	2.7	1
123	How systemic inflammation modulates adenosine metabolism and adenosine receptor expression in humans in vivo. Critical Care Medicine, 2012, 40, 2609-2616.	0.9	23
124	The efficacy of renal angioplasty in patients with renal artery stenosis and flash oedema or congestive heart failure: a systematic review. European Journal of Heart Failure, 2012, 14, 773-781.	7.1	23
125	Targeting adenosine receptors in the development of cardiovascular therapeutics. Expert Review of Clinical Pharmacology, 2012, 5, 199-218.	3.1	20
126	Improved resistance to ischemia and reperfusion, but impaired protection by ischemic preconditioning in patients with type 1 diabetes mellitus: a pilot study. Cardiovascular Diabetology, 2012, 11, 124.	6.8	24

#	Article	IF	Citations
127	Dipyridamole augments the antiinflammatory response during human endotoxemia. Critical Care, 2011, 15, R289.	5.8	35
128	Circulating adenosine increases during human experimental endotoxemia but blockade of its receptor does not influence the immune response and subsequent organ injury. Critical Care, 2011, 15, R3.	5.8	32
129	Modulation of Innate Immunity by Adenosine Receptor Stimulation. Shock, 2011, 36, 208-215.	2.1	33
130	The cardioprotective effects of metformin. Current Opinion in Lipidology, 2011, 22, 445-453.	2.7	108
131	The Cardiovascular Effects of Methylxanthines. Handbook of Experimental Pharmacology, 2011, , 413-437.	1.8	67
132	Endotoxin tolerance does not limit mild ischemia-reperfusion injury in humans in vivo. Innate Immunity, 2009, 15, 360-367.	2.4	9
133	Acute and long-term cardiovascular effects of coffee: Implications for coronary heart disease. , 2009, 121, 185-191.		123
134	Ischaemic Preconditioning and Postconditioning do not Affect Adenosine A1 and A2A Receptor Sensitivity. Cardiovascular Drugs and Therapy, 2009, 23, 415-417.	2.6	4
135	Metformin Prevents Myocardial Reperfusion Injury by Activating the Adenosine Receptor. Journal of Cardiovascular Pharmacology, 2009, 53, 373-378.	1.9	68
136	Wake Up and Smell the Coffee: Yet Another No Go for Cardiac Patients?. Cardiovascular Drugs and Therapy, 2008, 22, 257-259.	2.6	3
137	Human in vivo research on the vascular effects of adenosine. European Journal of Pharmacology, 2008, 585, 220-227.	3.5	27
138	Erythropoietin: ready for prime-time cardioprotection. Trends in Pharmacological Sciences, 2008, 29, 258-267.	8.7	61
139	The 22G> A polymorphism in the adenosine deaminase gene impairs catalytic function but does not affect reactive hyperaemia in humans in vivo. Pharmacogenetics and Genomics, 2008, 18, 843-846.	1.5	27
140	Augmented hyperaemia and reduced tissue injury in response to ischaemia in subjects with the 34C > T variant of the AMPD1 gene. European Heart Journal, 2007, 28, 1085-1091.	2,2	22
141	Acute elevation of plasma non-esterified fatty acids increases pulse wave velocity and induces peripheral vasodilation in humans in vivo. Clinical Science, 2007, 113, 33-40.	4.3	8
142	The 1976C>T polymorphism in the adenosine A2A receptor gene does not affect the vasodilator response to adenosine in humans in vivo. Pharmacogenetics and Genomics, 2007, 17, 551-554.	1.5	14
143	DNA methylation status is not impaired in treated cystathionine beta-synthase (CBS) deficient patients. Molecular Genetics and Metabolism, 2007, 91, 55-60.	1.1	19
144	Antibodies against the CUB1-2 domains of ADAMTS13 in a patient with benign monoclonal gammopathy: no causal relationship. Haematologica, 2007, 92, e74-e76.	3.5	6

#	Article	IF	CITATIONS
145	Effect of the 34C>T variant in theAMPD1 gene on the clinical response to methotrexate in patients with rheumatoid arthritis: Comment on the article by Wessels et al. Arthritis and Rheumatism, 2007, 56, 694-694.	6.7	1
146	Caffeine Prevents Protection in Two Human Models of Ischemic Preconditioning. Journal of the American College of Cardiology, 2006, 48, 700-707.	2.8	65
147	Letter to the Editor. American Heart Journal, 2006, 151, e9.	2.7	6
148	The effect of adenosine receptor agonists on cytokine release by human mononuclear cells depends on the specific Toll-like receptor subtype used for stimulation. Cytokine, 2006, 35, 95-99.	3.2	19
149	Protective effects of adenosine A2A agonist during hemorrhagic shock: A simple intervention may result in a complex response. Critical Care Medicine, 2006, 34, 3059.	0.9	0
150	Oral therapy with dipyridamole limits ischemia-reperfusion injury in humans. Clinical Pharmacology and Therapeutics, 2005, 78, 52-59.	4.7	48
151	In vivo evidence against a role for adenosine in the exercise pressor reflex in humans. Journal of Applied Physiology, 2005, 99, 522-527.	2.5	20
152	Enhanced Cellular Adenosine Uptake Limits Adenosine Receptor Stimulation in Patients With Hyperhomocysteinemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 109-114.	2.4	36
153	Annexin A5 Scintigraphy of Forearm as a Novel In Vivo Model of Skeletal Muscle Preconditioning in Humans. Circulation, 2005, 111, 173-178.	1.6	47
154	Reduced adenosine receptor stimulation as a pathogenic factor in hyperhomocysteinemia. Clinical Chemistry and Laboratory Medicine, 2005, 43, 1001-6.	2.3	9
155	Potential role for adenosine in the pathogenesis of the vascular complications of hyperhomocysteinemia. Cardiovascular Research, 2003, 59, 271-276.	3.8	40
156	Stress Susceptibility As a Determinant of Endothelium-dependent Vascular Reactivity in Rat Mesenteric Arteries. Journal of Cardiovascular Pharmacology, 2003, 41, 625-631.	1.9	2
157	Stress Susceptibility as a Determinant of the Response to Adrenergic Stimuli in Mesenteric Resistance Arteries of the Rat. Journal of Cardiovascular Pharmacology, 2002, 40, 678-683.	1.9	7
158	Gut Microbial Structural Variations as Determinants of Human Bile Acid Metabolism. SSRN Electronic Journal, 0, , .	0.4	0
159	Gut Microbial Structural Variations as Determinants of Human Bile Acid Metabolism. SSRN Electronic Journal, 0, , .	0.4	0